India, May 28 -- Natera Inc. (NTRA), a diagnostics and precision medicine company, on Thursday reported enrollment of the first patient in the SIGNAL-ER 101 study for Signatera MRD tests to facilitate diagnosis and directed treatments in early-stage breast cancer.
Signatera is an assay test developed to detect circulating DNA (ctDNA) to identify minimal residual disease (MRD). Patients of intermediate-risk, HR+/HER- early-stage breast cancer are usually treated with a combination of CDK4/6 inhibitors and endocrine therapy, but these yield benefit in only 3% of cases.
However, upon identification of MRD negative status, patients can defer CDK4/6 inhibitor treatment in favor of endocrine therapy, which shows a 95% recurrence-free success ra...